Today, more than ever, pharmaceutical and biotech companies are under great pressure to run their business in a way that makes drug development processes more efficient and cost-effective. A big factor in these staggering rates is the increasing complexity of clinical trials, driven in large part by trial sponsors needing to evaluate more endpoints to demonstrate product value. Prakriteswar Santikary of ERT discusses how this is where the dynamic trio of artificial intelligence (AI), the cloud and a data lake comes in.